Superparamagnetic iron oxide nanoparticles (SPIONs) could overcome the shortcomings of current in situ amorphization methods by using magnetic hyperthermia. SPIONs (Fe3O4 or γ-Fe2O3) are non-toxic, biocompatible, biodegradable and efficiently cleared from the body via the iron metabolism pathway. They are approved by the US Food and Drug Administration (FDA) as oral magnetic resonance imaging contrast agents (Ferumoxsil) and for treatment of anemia (Ferumoxytol) in patients with chronic kidney disease. SPIONs release heat locally upon exposure to an alternating magnetic field (AMF) due to relaxation losses. The heat dissipation from SPIONs on exposure to an AMF is the result of relaxation of the magnetic moment within the particle (Néel relaxation) or the rotation of the particle itself (Brownian relaxation). So far, this property of SPIONs, commonly termed magnetic hyperthermia, has been used for treatment of cancer and triggered drug delivery. The heat dissipation properties can be enhanced by careful engineering of the SPION properties, e.g., with unidirectional growth of nanoparticles, doping with metals, size optimization, and formation of nanocrystal clusters. In particular, spinel crystal nanostructures of e.g. iron oxide doped with Zn 2+ or Mn 2+ release more heat than pure iron oxides. In this work, we demonstrate for the first time the use of SPIONs to induce amorphization of a poorly aqueous soluble crystalline drug (celecoxib), in tablets for oral administration (Figure ). Celecoxib, a cyclooxygenase-2 inhibitor widely used to treat osteoarthritis and rheumatoid arthritis, was chosen as the model drug due to its low aqueous solubility and poor bioavailability.